ISSN: 2161-0681
Journal of Clinical & Experimental Pathology
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 2975
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Cosmos IF
- Ulrich's Periodicals Directory
- RefSeek
- Directory of Research Journal Indexing (DRJI)
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
- world cat
- journal seek genamics
- j-gate
- esji (eurasian scientific journal index)
Useful Links
Recommended Journals
Related Subjects
Share This Page
Updates in lung cancer staging
12th International Conference on Pediatric Pathology & Laboratory Medicine
R A Miller
Texas Medical Center, USA
Posters & Accepted Abstracts: J Clin Exp Pathol
DOI:
Abstract
The AJCC Cancer Staging Manual updates are scheduled to be published on or before October 31, 2016 and will be effective as of January 1, 2017. With regard to lung cancer staging, more emphasis will be placed on tumor size in the 8th edition in order to better stratify patient prognosis. Additional changes in the upcoming addition include factors such as diaphragm invasion, tumor distance from the main stem bronchus, concomitant atelectasis/pneumonitis, changes in nodal status, and changes in the metastatic category. Although therapeutic changes are not anticipated, the new addition is anticipated to place patients with newly diagnosed lung cancer into better prognostic categories. As such, as a practicing pathologist, it is essential to have a thorough understanding of lung cancer staging. The intent of this lecture will be to touch on the AJCC 8th edition updates and to discuss the rationale behind the various changes. Additionally, challenges will be discussed with regard to staging patients, such as appropriately determining tumor size, appropriate categorization of lung adenocarcinoma, and determining synchronous primaries versus metastatic lesions.Biography
Email: rmille01@gmail.com
